Advertisement
U.S. markets close in 5 hours 4 minutes
  • S&P 500

    5,253.64
    +5.15 (+0.10%)
     
  • Dow 30

    39,763.21
    +3.13 (+0.01%)
     
  • Nasdaq

    16,402.91
    +3.39 (+0.02%)
     
  • Russell 2000

    2,126.60
    +12.25 (+0.58%)
     
  • Crude Oil

    82.39
    +1.04 (+1.28%)
     
  • Gold

    2,233.90
    +21.20 (+0.96%)
     
  • Silver

    24.85
    +0.10 (+0.40%)
     
  • EUR/USD

    1.0805
    -0.0025 (-0.23%)
     
  • 10-Yr Bond

    4.1980
    +0.0020 (+0.05%)
     
  • GBP/USD

    1.2637
    -0.0001 (-0.01%)
     
  • USD/JPY

    151.2140
    -0.0320 (-0.02%)
     
  • Bitcoin USD

    71,411.13
    +1,636.90 (+2.35%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,967.28
    +35.30 (+0.45%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Acasti Pharma to Present at Biotech Showcase Conference

LAVAL, QUEBEC--(Marketwired - Jan 2, 2018) - Acasti Pharma Inc. (ACST)(TSX VENTURE:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that Jan D'Alvise, the company's president and chief executive officer will present at Biotech Showcase Conference on Wednesday, January 10 at 11:00 a.m. PT in Yosemite - A of the Ballroom Level. The conference will take place at the Hilton San Francisco Union Square.

A live audio webcast of the presentation will be available under the "News & Investors" section of Acasti's website at www.acastipharma.com. A replay of the presentation will be available for 60 days following the event.

About Acasti Pharma

Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre® (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. The company's strategy is to initially develop and commercialize CaPre for the 3 to 4 million patients in the U.S. with severe hypertriglyceridemia. Since its founding in 2008, Acasti Pharma has focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the major blood lipids associated with cardiovascular disease risk. For more information, visit www.acastipharma.com.

Advertisement